Biodexa Pharmaceuticals (BDRX) Enterprise Value (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Enterprise Value of -$11.4 million for Q4 2025, down 110.83% sequentially from -$5.4 million in Q2 2025, and down 429.91% YoY from $3.4 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Enterprise Value (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Enterprise Value for 13 years, with the latest figure at -$11.4 million in Q4 2025.
- Quarterly Enterprise Value fell 429.91% year-over-year to -$11.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.4 million (down 429.91% YoY) and the FY2025 annual result came in at -$11.3 million, down 425.27% from the prior year.
- Enterprise Value eased to -$11.4 million in Q4 2025 per BDRX's latest filing, from -$5.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$2.1 million in Q4 2024 and troughed at -$13.6 million in Q4 2021.
- A 5-year average of -$7.0 million and a median of -$6.5 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value jumped 75.46% in 2022, then sank 429.91% in 2025.
- Over 5 years, Enterprise Value stood at -$13.6 million in 2021, then surged by 75.46% to -$3.3 million in 2022, then plunged by 122.79% to -$7.4 million in 2023, then surged by 71.09% to -$2.1 million in 2024, then tumbled by 429.91% to -$11.4 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$11.4 million, -$5.4 million, and -$2.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | -11.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.35 Mn |
| Jun 30, 2025 | -5.38 Mn |
| Dec 31, 2024 | -2.14 Mn |
| Jun 30, 2024 | -6.38 Mn |
| Dec 31, 2023 | -7.41 Mn |
| Jun 30, 2023 | -6.54 Mn |
| Dec 31, 2022 | -3.33 Mn |
| Jun 30, 2022 | -8.09 Mn |
| Dec 31, 2021 | -13.56 Mn |
| Jun 30, 2021 | -5.88 Mn |
| Dec 31, 2020 | -9.96 Mn |
| Jun 30, 2020 | -5.37 Mn |
| Dec 31, 2019 | -14.05 Mn |
| Jun 30, 2019 | -11.55 Mn |
| Dec 31, 2018 | -3.01 Mn |
| Jun 30, 2018 | -5.61 Mn |
| Dec 31, 2017 | -17.53 Mn |
| Jun 30, 2017 | -7.90 Mn |
| Dec 31, 2016 | -21.89 Mn |
| Jun 30, 2016 | -10.38 Mn |